+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Conatus Pharmaceuticals - logo

Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Its lead compound, emricasan, is a first-in-class, orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases. In December 2016, Conatus announced an exclusive option, collaboration and license agreement with Novartis for the global development and commercialization of emricasan. The company was founded in 2005 and is headquartered in San Diego, California.

Renal Diseases Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Renal Diseases Drug Development Pipeline Review, 2018

  • Report
  • December 2018
  • 154 Pages
From
From
From
NASH Drugs Market, 2015 - 2025 - Product Thumbnail Image

NASH Drugs Market, 2015 - 2025

  • Report
  • September 2015
  • 188 Pages
From
Emricasan (Conatus/Novartis) Drug Overview 2019 - Product Thumbnail Image

Emricasan (Conatus/Novartis) Drug Overview 2019

  • Report
  • July 2019
  • 12 pages
From
Chronic Kidney Disease (CKD) - Pipeline Insight, 2020 - Product Thumbnail Image

Chronic Kidney Disease (CKD) - Pipeline Insight, 2020

  • Drug Pipelines
  • September 2020
  • 104 pages
From
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2020 - Product Thumbnail Image

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 pages
From
Loading Indicator
adroll